<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183674</url>
  </required_header>
  <id_info>
    <org_study_id>10922213.7.0000.0068-2</org_study_id>
    <nct_id>NCT03183674</nct_id>
  </id_info>
  <brief_title>Oxytocin in Spectrum Autism Disorders</brief_title>
  <acronym>OxytocinASD</acronym>
  <official_title>Oxytocin in Individuals With Spectrum Autism Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe effects of oxytocin on individuals with autism spectrum disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To observe the effects of oxytocin on individuals with autism spectrum disorder according to
      gender, in facial recognition and eye tracking tests. The investigators will apply the nepsy
      and eye tracking tests before and 45 minutes after the puff with oxytocin or placebo at the
      dose of 0.4 IU / kg / dose maximum of 24 IU. The next week the volunteer will return and will
      do the same procedure because whoever took the placebo would take oxytocin and vice versa. Is
      a randomized, double-blind, placebo-controlled clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Anticipated">May 15, 2018</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye tracking</measure>
    <time_frame>on average of 1 year</time_frame>
    <description>Eye tracking program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nepsy</measure>
    <time_frame>on average of 1 year</time_frame>
    <description>face recognize</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Autistic Disorder</condition>
  <arm_group>
    <arm_group_label>oxytocin spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxytocin nose spray dose 0,4IU/kg, once unique dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline nose spray, 0,9 %, once unique dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Single dose oxytocin 45 minutes before the test</description>
    <arm_group_label>oxytocin spray</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline solution 0,9% spray nasal</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Diagnosis of ASD by DSMV

          -  CARS&gt; 30

          -  age between 3 and 16 years

          -  stable (3 months with medication maintained or without medication)

        Exclusion Criteria:- pregnant women, infants and

          -  participation in another research project of pharmacological or behavioral
             intervention in progress

          -  Use of pituitary hormones, cortisol, androgens and estrogens.

          -  heart problems: recent AMI, heart failure.

          -  respiratory problems: pneumonia, respiratory failure, decompensated asthma, acute
             bronchitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debora Zambori</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Psiquiatria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Psiquiatria</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04117-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Helena Paula Brentani</investigator_full_name>
    <investigator_title>Prof. DRa</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators intend to share research information, such as, harms and benefits</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

